Potential Therapies for Infectious Diseases Based on Targeting Immune Evasion Mechanisms That Pathogens Have in Common With Cancer Cells

Jodi Wong 1†, Stephen Yiu Chuen Choi 1,2,3†, Rongrong Liu 4, Eddie Xu 1,2,3, James Killam 2, Peter W. Gout 1* and Yuzhuo Wang 1,2,3*

1 Department of Experimental Therapeutics, BC Cancer Research Centre, Vancouver, BC, Canada, 2 Vancouver Prostate Centre, Vancouver, BC, Canada, 3 Department of Urologic Sciences, The University of British Columbia, Vancouver, BC, Canada, 4 Department of Microbiology, School of Basic Medicine, Fourth Military Medical University, Xi’an, China

Many global infectious diseases are not well-controlled, underlining a critical need for new, more effective therapies. Pathogens and pathogen-infected host cells, like cancer cells, evade immune surveillance via immune evasion mechanisms. The present study indicates that pathogenic bacteria, endoparasites, and virus-infected host cells can have immune evasion mechanisms in common with cancers. These include entry into dormancy and metabolic reprogramming to aerobic glycolysis leading to excessive secretion of lactic acid and immobilization of local host immunity. The latter evasion tactic provides a therapeutic target for cancer, as shown by our recent finding that patient-derived cancer xenografts can be growth-arrested, without major host toxicity, by inhibiting their lactic acid secretion (as mediated by the MCT4 transporter)-with evidence of host immunity restoration. Accordingly, the multiplication of bacteria, endoparasites, and viruses that primarily depend on metabolic reprogramming to aerobic glycolysis for survival may be arrested using cancer treatment strategies that inhibit their lactic acid secretion. Immune evasion mechanisms shared by pathogens and cancer cells likely represent fundamental, evolutionarily-conserved mechanisms that may be particularly critical to their welfare. As such, their targeting may lead to novel therapies for infectious diseases.

Keywords: immune evasion, pathogen, bacteria, endoparasite, virus, cancer, metabolic reprogramming, aerobic glycolysis

INTRODUCTION

Infectious diseases constitute a major health problem worldwide and impose a substantial burden on societies in human suffering and economic loss. While diseases like smallpox have essentially been eliminated, many other pathogen-induced diseases are not well-controlled and new infectious diseases are continually emerging, thus underlining a critical need for novel therapeutic targets leading to more effective therapies (Fonkwo, 2008).
The human body is constantly under attack by foreign microorganisms such as pathogenic bacteria, parasites, and viruses, i.e., pathogens whose invasion of the body and subsequent multiplication can lead to a wide variety of global infectious diseases. In defense of the body, invading pathogens are identified by the innate immune system as "non-self" via cell surface pattern recognition receptors (PRRs) on innate immune cells which recognize pathogen-associated molecular patterns (PAMPs) on the foreign microbes; the latter are then eliminated by, for example, macrophage-mediated phagocytosis or secretion of cytotoxins by NK cells (Chaplin, 2010; Vaure and Liu, 2014).

Recognition of foreign microbes by adaptive immunity is based on the ability of T- and B-lymphocytes to distinguish self from non-self-antigens via cell surface antigen-specific receptors, i.e., T-cell receptors (TCRs) and B-cell receptors (BCRs). Identification of pathogen-infected host cells is achieved by T cells via recognition of antigen fragments presented by major histocompatibility complex (MHC) molecules. Elimination of the intruders is accomplished via cytotoxic responses by CD8+ T cells and CD45+ lymphocytes, recruitment of neutrophils, monocytes, and mature B lymphocytes (mediated by CD4+ helper T cells), as well as antibody production by plasma cells.

In addition to foreign microorganisms, host cancer cells can be recognized by the immune system as changes in their cell surface structure render them foreign (Chaplin, 2010).

Despite vigorous immune surveillance by healthy, immunocompetent hosts, pathogens often manage to survive in the body. They accomplish this by employing a large variety of immune evasion mechanisms based on, for example, immobilizing immune responses or avoiding recognition by host immune cells (Finlay and McFadden, 2006; Reddick and Alto, 2014). Such survival tactics can also be used by cancer cells (Chaplin, 2010; Vinay et al., 2015). In the last decade it has become evident that metabolic reprogramming to aerobic glycolysis (the Warburg effect) is a key mechanism that most cancer types use to evade host immune surveillance, as the resulting increases in lactic acid levels and acidity of the tumor microenvironment immobilizes host immune cell activity (Fischer et al., 2007; Choi et al., 2013; Brand et al., 2016). As recently shown, this immune evasion tactic provides a target for cancer therapy (Choi et al., 2016, 2018).

In the present study, we have compared immune evasion mechanisms of pathogens (i.e., bacteria, endoparasites, and virus-infected host cells) and human cancer cells in search of mechanisms common to both groups. Such shared tactics may represent fundamental, evolutionarily-conserved mechanisms of immune evasion, which could in turn be useful as targets for novel therapies of both cancer and infectious diseases.

**IMMUNE EVASION MECHANISMS EMPLOYED BY PATHOGENS AND CANCER CELLS**

A literature survey led to the following information.

### Pathogenic Bacteria

A small percentage of bacterial species can cause globally significant diseases such as tuberculosis and pneumonia. A typical immune response to pathogenic bacteria consists of opsonisation of the microbes followed by phagocytosis by host macrophages and fusion of the phagosomes with lysosomes. Intra-lysosomal acid hydrolases, reactive oxygen species (ROS) and nitric oxide ultimately kill the pathogens (van Kessel et al., 2014).

Bacteria have developed a number of immune evasion mechanisms and methods to manipulate host machinery to promote their survival and proliferation. They can avoid recognition by TLRs by masking their surface antigens with a carbohydrate capsule (Finlay and McFadden, 2006) or through alterations of cell surface lipids (Cambier et al., 2014). Some bacterial species are able to subvert the phagocytic process by secreting proteinaceous effectors into the host cell via their "type three secretion systems" (T3SS) (Quitard et al., 2006) to target host actin remodeling required for phagocytosis (Finlay and McFadden, 2006) and to promote entry into host cells (Betts et al., 2009; da Cunha et al., 2014). Other species manage to use the host intracellular environment for proliferation, with *Mycobacterium tuberculosis*, *Coxiella burnetii*, and *Listeria monocytogenes* residing in macrophages, *Salmonella enterica* in the intestinal epithelium, *Mycobacterium leprae* in connective and nerve tissues, and *Chlamydia trachomatis* in ocular and urogenital tissues (Betts et al., 2009; da Cunha et al., 2014). The MAPK/NF-κB pro-inflammatory pathway can also be targeted by bacterial proteases to inhibit an inflammatory response, and TLR signaling can be modulated to secrete the immunosuppressive cytokine IL-10 (Finlay and McFadden, 2006).

When phagocytosed, bacteria employ various strategies to survive. Commonly, they escape the phagosomal environment prior to its lysosome-mediated acidification: *Shigella* and *L. monocytogenes* escape by remodeling host actin and secreting phospholipases to cleave the phagosomal membrane (Small et al., 1994; Baxt et al., 2013). Some bacteria, such as *M. tuberculosis*, prevent the acidification of the phagosome by disrupting phagosome-lysosome fusion using the PtpA tyrosine phosphatase (Bach et al., 2008). Others exploit the phagosome to create a suitable microenvironment in which to proliferate: *Legionella pneumophila* creates a vacuolar environment specifically lacking MHC class II molecules, thereby protecting itself from innate immunity (Clemens and Horwitz, 1992), whereas *C. burnetii* requires an acidic environment for growth and virulence (Maurin et al., 1992).

In response to attack by the immune system, bacteria can enter a hardy, non-replicating state, termed dormancy, for protection (Rittershaus et al., 2013). Dormancy comes as two different types: (i) cellular quiescence, a period of reduced cellular growth that maintains a basal metabolism as observed for persistent *M. tuberculosis* (Betts et al., 2002) and (ii) true dormancy, a metabolically-arrested spore state promoting survival under adverse conditions, as exhibited by the difficult-to-treat *Clostridium* genus (Rittershaus et al., 2013). Cellular quiescence is achieved through stress-triggered expression of dormancy-related genes, e.g., activation of signaling system-related genes.
such as the type II toxin-antitoxin (TA) module and tnaA, a gene responsible for the conversion of tryptophan to indole, an intracellular signaling molecule responsible for mediating persistence (Wood et al., 2013; Pu et al., 2017).

Bacteria can also evade innate immunity by reprogramming their energy metabolisms. Staphylococcus aureus, in its hypoxic phagosomal environment, upregulates glycolysis and lactic acid fermentation in order to maintain a redox balance in response to immune-induced nitric oxide stress (Vitko et al., 2015). When glucose is abundant, Escherichia coli reprograms glycolysis toward the production of acetate in its exponential growth (Dittrich et al., 2005). Intra-macrophagic Brucella abortus induces a shift toward aerobic glycolysis in its host—a mechanism shown to be required for its survival (Czyz et al., 2017). The lactic acid and derivative short-chain fatty acids (SCFAs) produced by the bacteria are secreted in order to maintain an alkaline intracellular pH (Konings et al., 1997). The lactic acid and SCFAs may also act as immune-modulatory signaling molecules, as their production by the gut microbiota generates an immune-tolerogenic environment by promoting Treg cell differentiation and inhibiting epithelial cell proliferation (Thangaraju et al., 2009; Iraporda et al., 2015; Asarat et al., 2016; Corrêa-Oliveira et al., 2016). Other evidence shows that volatile bacterial SCFAs can markedly inhibit T- and B-cell proliferation (Kurita-Ochiai et al., 1995).

**Pathogenic Endoparasites**

Endoparasites, i.e., parasites living inside the human body, can be grouped into two main categories: single-celled protozoa and multicellular worms, helminths. Both require successful evasion of the host immune system for survival and reproduction (Cox, 2002).

Protozoa employ several adaptive mechanisms to avoid contact with immune cells, often seeking residence in immune privileged sites. Plasmodium falciparum, which causes malaria in humans, produces SPECT-1 and -2 proteins allowing it to evade humoral immunity while traveling to the liver where it can mature in a relative immune privileged environment (Patarroyo et al., 2011). It then travels in the peripheral blood and infects erythrocytes, which lack MHC I receptors, and hence cannot be targeted by cytotoxic immune cells (Gomes et al., 2016). Trypanosoma Brucei, causing African sleeping disease, proliferates in blood and lymph and invades the central nervous system—another immune privileged site (Masocha et al., 2007). Migrating helminths also evade immune attack by remaining in the central nervous system and liver (Pockros and Capozza, 2005). Polymorphism also plays a role in immune evasion by protozoa. P. falciparum, for example, go through multiple stages during their lifetime and alter their surface antigens after every stage, whereas T. Brucei survives through subsurface protein remodeling which is involved in signaling transitions during developmental stages of dormancy and disease progression (Batram et al., 2014). These polymorphic modifications downgrade the ability of B cells to make highly specific antibodies (Zambrano-Villa et al., 2002).

Another mechanism via which endoparasites survive the host defense is through immunomodulation; some protozoa are able to induce host T cell anergy through suppression of co-stimulators and cytokines (Zambrano-Villa et al., 2002; Rodrigues et al., 2014). T. brucei uses its “vector host” to its advantage, in which the saliva of the Tsetse fly transmitted along with the parasite contains a peptide which suppresses human host release of cytokines TNF-α, IFN-γ, IL-6, and IL-10 (Bai et al., 2015; Stijlemans et al., 2016). Helminths are able to survive in humans for many years due to their ability to secrete immunomodulatory products (Hewitson et al., 2009).

Entry into a dormant state is also a survival strategy of some endoparasites, with stress-induced dormancy allowing their persistence under adverse conditions. In particular, induction of cell cycle arrest by ring-stage P. falciparum has been observed following use of traditional anti-malarial artemisinin-based combination treatments (Witkowski et al., 2010) and amino acid starvation (McLean and Jacobs-Lorena, 2017). The dormant subpopulations upregulate key survival genes (e.g., genes encoding heat shock proteins), downregulate cell cycle regulators and DNA biosynthesis proteins, and sustain their energy needs through fatty acid synthesis and pyruvate metabolism. Importantly, drug-selected parasites were able to re-enter growth and development upon stress removal (Witkowski et al., 2010), accentuating an ever-pressing issue of parasitic persistence in disease treatment.

The metabolic profiles of endoparasites can also be modulated in response to variations in their environment and developmental stage. In proliferative stages, protozoa and helminths can display a preferred dependence on anaerobic glycolysis and lactic acid production for ATP generation. The intra-erythrocytic Plasmodium parasite displays deregulated glycolytic activity coupled to impaired mitochondrial metabolism, hypothesized to provide a distinct growth advantage during its proliferative stage (Salcedo-Sora et al., 2014). Parasitic helminths can proliferate in high oxygen environments with or without aerobic respiration, indicating a preference for aerobic glycolysis as well (Tielens, 1994).

**Pathogenic Viruses**

Viruses can cause a wide variety of diseases such as influenza, HIV/AIDS and Ebola. They employ various strategies to evade and suppress the human host immune response. Primarily, viruses contain high sequence variability, which contributes to immune escape via interruption and alteration of antigen presentations from virus-infected cells (Balamurugan et al., 2017; Karlsson Hedestam et al., 2017). Influenza viruses, for example, evolve rapidly in a process called “antigenic drift,” gaining mutations in genes involved in antigen binding (Peacock et al., 2017; Wu and Wilson, 2017). Other mechanisms include T cell exhaustion leading to loss of cytotoxic function (Wieland et al., 2017) and reduced presentation of MHC class I and NKG2D molecules resulting in inadequate immune activation (Pymm et al., 2017; Schmiedel and Mandelboim, 2017).

Immune surveillance of viral pathogens is largely accomplished via intracellular sensors that detect viral RNA and DNA (Ma and Damania, 2016; Roy et al., 2016; Nerbøvik et al., 2017). Viruses can suppress the immune response by interfering
with antiviral signaling pathways, particularly by modifying their nucleic acids, inhibiting proper expression of PRRs and their adaptors (Chan and Gack, 2016), and suppressing the production of antiviral cytokines (Zou et al., 2016). For example, the Seneca Valley virus can inhibit interferon responses by targeting host adaptors (Qian et al., 2017), and Dengue and West Nile viruses can block IFN-α/β receptors (Gack and Diamond, 2016). Furthermore, the role of gene-silencing microRNAs produced by human polyomaviruses has been found to downregulate expression of large T antigen, a target of antiviral immunity, thus mediating the immune escape and survival of the viruses (Martelli and Giannechini, 2017).

Another immune evasion tactic of viruses consists of entering a dormant state within a host cell, with subsequent viral reactivation once cell immunity wanes. Cells infected with viruses that have become dormant upregulate expression of latency-associated genes, but not lytic viral genes, making immune detection of the viruses difficult (Phelan et al., 2017). Notably, HPV can, upon infection, either actively replicate or assume a state of dormancy (Hoppe-Seyler et al., 2017a,b). It has also been shown that migrating HIV-infected cells can reactivate following dormancy with differential response to drugs (Bohn-Wippert et al., 2017). Mechanisms underlying viral dormancy include epigenetic regulation in response to host-induced stressors; for example, binding of the innate immune sensor, IFI16, to the lytic gene promoter in KSHV-infected cells results in transcriptional repression of latent KSHV (Roy et al., 2016). Furthermore, post-translational histone modifications have also been associated with decreased antigen expression (Bloom et al., 2010; Arbuckle et al., 2017).

To optimize their environment for infection, viruses can alter many host cellular metabolic pathways; in particular, cells infected by actively replicating viruses exhibit cancer phenotypes such as aerobic glycolysis, upregulated glutaminolysis and fatty acid synthesis (Sanchez and Lagunoff, 2015). Viruses such as HBV, HIV, and Zika have been shown to dysregulate glycolysis by increasing GLUT1 expression, glucose influx and lactic acid production in their host cells (Masson et al., 2017). Moreover, an acidified microenvironment resulting from increased lactic acid secretion may contribute to virus-induced pathogenesis, as enveloped viruses’ fusion to host cell membrane was observed to be more effective at a low pH (Desai et al., 2017). The fusion rate of the Ebola virus can also be increased by a brief exposure to an acidic environment (Markosyan et al., 2016).

**Cancer Cells**

Although cancer cells originate from the human host, they can be recognized by the immune system as non-self due to changes in their cell surface structures, and must evade immune recognition to survive. They can accomplish this by masking their cancer-specific surface neoantigens to prevent recognition by NK and effector T cells, and by suppressing antitumor immune responses (Mohme et al., 2017). MHC class I molecules on tumor cell surfaces are often weakly expressed or lacking, thus precluding cytotoxic T-cell responses (Garrido et al., 1993). In another strategy, cancer cells incorporate host platelet-derived vesicles exhibiting MHC I molecules on their plasma membrane to disguise themselves with regular host antigens (Placke et al., 2012). Moreover, immune recognition was found to be reduced via downregulation of NKG2D, a transmembrane NK cell receptor complex in pancreatic, gastric, colorectal, and breast cancers (Wang et al., 2016; Bi and Tian, 2017), while the inhibitory PD-1/PD-L1 signaling pathway was upregulated (Munn and Bronte, 2016). Suppression of the immune system can also be achieved through activation of indoleamine 2,3-dioxygenase (IDO), an inducible enzyme that catalyzes the rate-limiting step in tryptophan catabolism. Elevated levels of IDO are produced by a variety of malignancies (Munn and Mellor, 2016) and result in IDO-induced degradation of tryptophan to kynurenine. This metabolite promotes T_reg differentiation (Chen et al., 2008), while tryptophan at diminished levels cannot activate mTORC1, an enzyme required for T-cell proliferation (Moon et al., 2015).

Cancer cells are also able to avoid immune surveillance by entering a latent state, termed tumor dormancy (Aguirre-Ghiso, 2007; Crea et al., 2015; Dong et al., 2017). Dormancy-capable cells, which express growth-inhibitory signals, self-impose a slow-cycling state and upregulate expression of pluripotency and self-renewal genes (Sosa et al., 2015; Malladi et al., 2016). Circulating tumor cells also adopt this dormant pro-survival phenotype (Mohme et al., 2017). Changes in the surrounding environment may awaken dormant cells into an immune-tolerogenic proliferative state.

A major immune evasion mechanism of cancers consists of reprogramming glucose metabolism to aerobic glycolysis (the Warburg effect) as distinct from the mitochondrial oxidative phosphorylation pathway used by normal cells (Warburg, 1956; Gatenby and Gillies, 2004; Choi et al., 2013; Agrawal and Rangarajan, 2015; Wong et al., 2015). The resulting excessive secretion of lactic acid by cancer cells, mediated by monocarboxylate transporters, MCT1 and MCT4, leads to abnormally high extracellular lactic acid levels and acidification of the tumor microenvironment; elevated MCT1 and MCT4 levels have been associated with poor cancer prognosis (Polanski et al., 2014; Marchiq and Pouysségur, 2016; Noble et al., 2017), with MCT4 being a main exporter of lactate from glycolytic tissues (Ullah et al., 2006). The highly elevated levels of extracellular lactic acid and decreased pH in the microenvironment act in combination to inhibit lactic acid secretion by T lymphocytes of both innate and adaptive immunity (Fischer et al., 2007; Calcinoatto et al., 2012), thus reducing their glycolytic flux-dependent immune functions (Fischer et al., 2007; Calcinoatto et al., 2012; Loftus and Finlay, 2016). The resultant intracellularly acidified immune cells undergo decreased metabolism and acidosis while the low-pH environment indirectly impairs cytokine production and secretion, both effects resulting in local immunosuppression (Fischer et al., 2007; Calcinoatto et al., 2012; Chang et al., 2013; Tan et al., 2015; Paul et al., 2016; Bi and Tian, 2017). Aerobic glycolysis also has several proliferative advantages for cancers as the glycolytic intermediates can be used for biosynthesis of nucleotides and lipids essential for rapid cell proliferation (Lunt and Vander Heiden, 2011). The conversion of pyruvate to lactate is coupled to the
redonversion of cofactor NADH to NAD⁺, which is essential for maintaining the glycolytic flux and intracellular redox status (Lunt and Vander Heiden, 2011). The acidic tumor microenvironment may also promote cancer growth by inducing epigenetic changes toward a proliferative stem cell-like profile in solid tumors (Som et al., 2016). Moreover, lactate itself can act as a signaling molecule responsible for immune modulation, mediating M2-polarization of tumor-associated macrophages, resulting in secretion of angiogenic factors and inducing tissue-remodeling inflammation (Shime et al., 2008; Colegjo et al., 2014; Roszer, 2015).

**DISCUSSION**

As highlighted by this study, pathogenic bacteria, endoparasites and virus-infected host cells employ, like cancer cells, a large variety of mechanisms to evade immune surveillance. These mechanisms are diverse and multifaceted and, even within the four classes, various species may have their own unique methods of evading immune surveillance. As such, it is beyond the scope of this perspective article to elaborate on them. Further information can be obtained from the following literature references for pathogenic bacteria (Finlay and McFadden, 2006; Flannagan et al., 2015; Thammavongsa et al., 2015; Fisher et al., 2017; Karkhal et al., 2019), endoparasites (Cooper and Eleftherianos, 2016; Gomes et al., 2016; Nakada-Tsukui and Nozaki, 2016; Stijlemans et al., 2016; Wahlgren et al., 2017; Martinez-López et al., 2018), viruses (Finlay and McFadden, 2006; Chan and Gack, 2016; Agrawal et al., 2017; Felix and Savvides, 2017; Hsu, 2018; Soto et al., 2018), and cancer cells (Bhatia and Kumar, 2014; Vinay et al., 2015; Goodman et al., 2017; Bates et al., 2018).

Of special interest to us are the immune evasion mechanisms that the various pathogens share with cancer cells, as they likely represent fundamental, evolutionarily-conserved mechanisms that may be particularly critical to their welfare. Thus, such mechanisms could be useful as targets for novel therapies of both cancer and infectious diseases. In searching for such shared tactics two were found to be of paramount importance: (i) Metabolic reprogramming to aerobic glycolysis leading to excessive lactic acid secretion and consequent local host immunity suppression, a well-defined mechanism used by most human cancers (Gatenby and Gillies, 2004; Choi et al., 2013; Agrawal and Rangarajan, 2015) (Figure 1A). This tactic can also be used by pathogenic bacteria (Koning et al., 1997; Thangaraju et al., 2009; Irparida et al., 2015; Vitko et al., 2015; Asarat et al., 2015; Corrêa-Oliveira et al., 2016; Czyz et al., 2017), endoparasites (Tielens, 1994; Salcedo-Sora et al., 2014), and virus-infected cells (Sanchez and Laguanno, 2015; Markosyan et al., 2016; Desai et al., 2017; Masson et al., 2017). (ii) Entry into dormancy of pathogens or pathogen-infected host cells (Figure 1B), a less defined mechanism to avoid recognition by the immune system (Aguirre-Ghiso, 2007; Crea et al., 2015; Dong et al., 2017). It can be used by pathogenic bacteria (Betts et al., 2002; Rittershau et al., 2013; Wood et al., 2013; Pu et al., 2017), endoparasites (Witkowski et al., 2010; McLean and Jacobs-Lorena, 2017), and virus-infected cells (Bohn-Wipper et al., 2017; Hoppe-Seyler et al., 2017a,b; Phelan et al., 2017).

Excessive secretion of lactic acid by cancer cells due to metabolic reprogramming to aerobic glycolysis provides a new potential target for cancer therapy. This has been demonstrated by our recent discovery that treatment of advanced prostate cancer cells with antisense oligonucleotides (ASOs) targeting MCT4-mediated lactic acid secretion led to a marked reduction in MCT4 expression and lactic acid secretion, increased intracellular lactic acid levels, and marked reductions in aerobic glycolysis, cell proliferation, cell migration, and tissue invasion (Choi et al., 2016, 2018). Treatment of PC-3 tumor-bearing nude mice with the anti-MCT4 ASOs markedly inhibited tumor growth without inducing major host toxicity (Choi et al., 2016; Choi, 2017). In addition, a limited study of the effect of MCT4-targeting on restoration of host immunity was carried out using clinically relevant, first-generation subrenal capsule xenograft models of patient-derived advanced prostate cancer. Such first-generation models lack systemic functional host immunity, but exhibit viable patient tumor-associated immune cells (Dong et al., 2017). Importantly, treatment of these models with anti-MCT4 ASOs led to an increase in the number of human CD45+ lymphocytes and CD8+ cytotoxic T cells, indicative of restoration of the host anticancer immunity (Choi, 2017). These findings raise the possibility that pathogens, which use metabolic reprogramming to aerobic glycolysis as a main immune evasion tactic, can also benefit from therapy based on inhibition of lactic acid secretion, particularly as the mechanism underlying transporter-mediated lactic acid secretion is relatively simple.

Although we here have outlined our perspective regarding potential therapeutic intervention resulting from inhibiting lactic acid secretion, we realize that possible approaches to reversing immune evasion are as vast and varied as the mechanisms themselves (Beatty and Gladney, 2015; Spranger and Gajewski, 2018). Alternative methods of reactivating the anti-cancer immune response are being actively investigated, the most successful of which involve neutralizing antibodies targeting immune checkpoint inhibitors such as PD-1 and CTLA-4 (Alsaab et al., 2017; Sharpe and Pauken, 2018; Tang et al., 2018). Furthermore, multiple components within a particular key pathway can also be considered therapeutic targets. Beyond MCT4, additional transporters as well as enzymes associated with aerobic glycolysis are also considered candidates for therapeutic inhibition of cancer (Tennant et al., 2010; Cairns et al., 2011; Zhao et al., 2013). Taken together, strategies of reactivating anti-cancer immunity have recently been shown to be successful across a number of cancer types (Goodman et al., 2017; Cascone et al., 2018; Seidel et al., 2018), offering evidence both scientifically and clinically that immunomodulation can translate into effective therapies. Similar considerations may apply to pathogen-induced diseases.

Finally, an additional aspect worth exploring as a potential therapeutic approach would be the use of combination therapies targeting multiple biological phenomena as surveyed here. In particular, targeting the dormant cell/organism population in conjunction with the actively proliferating population could offer enhanced efficacy. Given the importance of aerobic
FIGURE 1 | Metabolic reprogramming to aerobic glycolysis and entry into dormancy: two common immune evasion mechanisms employed by proliferating bacteria, endoparasites, viruses, and cancer cells. The host immune evasion/suppression processes are regulated via gene mutation and epigenetic reprogramming. **(A)** Processes involved in aerobic glycolysis are represented. Cell cycle genes are greatly upregulated. The reprogrammed metabolism leads to increases in (i) glucose uptake via glucose transporters (green) and (ii) lactic acid and short chain fatty acid secretion via monocarboxylate transporters (red), generating an acidic microenvironment. The lowered pH and increased lactate levels are immunosuppressive, e.g., inhibiting cytotoxic T cell activation. **(B)** Processes underlying entry into and maintenance of dormancy are illustrated. Pluripotency genes (blue) are expressed, while the expression of cell-cycle progression genes (pink) is arrested. Viral genes (green) of virus-infected cells are not expressed. Limited-nutrient metabolism states are induced (e.g., autophagy, glyoxylate cycle). T cells, recognizing self-antigens, are not activated.

Metabolic reprogramming to rapid cellular proliferation and the significance of cells entering dormancy to avoid immune detection, a combined effort to inhibit both lactic acid secretion (e.g., by MCT4 inhibition as mentioned above) and the unique metabolic properties of dormant cells could eliminate a greater proportion of cancers and pathogenic microorganisms. While mechanisms underlying cellular entry into dormancy remain to be more fully elucidated, preliminary investigations...
in our laboratory have uncovered changes in amino acid metabolism as a potentially unique metabolic profile in dormant cancer cells post-therapy (Nabavi et al., 2017). As such, targeting the metabolic rewiring that occurs within the dormant state could help eliminate even difficult-to-target residual cells.

**CONCLUSION**

This study indicates that pathogenic bacteria, endoparasites, virus-infected host cells, and human cancer cells can share immune evasion mechanisms, i.e., (i) metabolic reprogramming to aerobic glycolysis leading to excessive lactic acid secretion and host immunity suppression and (ii) entry into dormancy. Targeting fundamental, evolutionarily-conserved mechanisms of immune evasion could be particularly effective for treatments of both cancer and multiple infectious diseases.

**AUTHOR CONTRIBUTIONS**

YW initiated the topic in July 2016. JW, SC, and PG organized the manuscript. RL and EX provided published evidence. JW, SC, JK, PG, and YW were involved in the further development of the ideas and the writing of the paper. PG finalized the write-up.

**FUNDING**

This study was supported in part by grants awarded to YW by the Canadian Institutes of Health Research (Grant No. 141635, 144159, 153081), the Urology Foundation and the Terry Fox Research Institute (Grant No. 1062).

**REFERENCES**

Agrawal, A., and Rangarajan, V. (2015). Appropriateness criteria of FDG PET/CT in oncology. *Indian J. Radiol. Imag.* 25, 88–101. doi: 10.4103/0971-3026.155823

Agrawal, P., Nawadkar, R., Ojha, H., Kumar, J., and Sahu, A. (2017). Complement evasion strategies of viruses: an overview. *Front. Microbiol.* 8:1117. doi: 10.3389/fmicb.2017.01117

Aguirre-Ghiso, J. A. (2007). Models, mechanisms and clinical evidence for cancer dormancy. *Nat. Rev. Cancer* 7, 834–846. doi: 10.1038/nrc2226

Alsaab, H. O., Sau, S., Alzhrani, R., Tatiparti, K., Bhise, K., Kashaw, S. K., et al. (2017). PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. *Front. Pharmacol.* 8:561. doi: 10.3389/fphar.2017.00561

Arbuckle, J. H., Gardina, P. J., Gordon, D. N., Hickman, H. D., Yewdell, J. W., Pierson, T. C., et al. (2017). Inhibitors of the histone methyltransferases EZH2/1 induce a potent antiviral state and suppress infection by diverse viral pathogens. *MBio* e00114-17. doi: 10.1128/mBio.01141-17

Asarat, M., Apostolopoulos, V., Vasiliev, T., and Donkor, O. (2016). Short-chain fatty acids regulate cytokines and Th17/treg cells in human peripheral blood mononuclear cells in vitro. *Immunol. Invest.* 45, 205–222. doi: 10.3109/08820139.2015.1122613

Bach, H., Papavinassundaram, K. G., Wong, D., Hmama, Z., and Av-Gay, Y. (2008). *Mycobacterium tuberculosis* virulence is mediated by PtpA dephosphorylation of human vacuolar protein sorting 33B. *Cell Host Microbe* 3, 316–322. doi: 10.1016/j.chom.2008.03.008

Bai, X., Yao, H., Du, C., Chen, Y., Lai, R., and Rong, M. (2015). An immunoregulatory peptide from tsetse fly salivary glands of Glossina morsitans morsitans. *Biochim. Biophys. Acta* 1849, 123–128. doi: 10.1016/j.bjchem.2015.09.001

Balamurugan, A., Claiborne, D., Ng, H. L., and Yang, O. O. (2017). HIV-1 polyomavirus variabilities is associated with t cell receptor repertoire instability and breadth. *J. Virol.* 91:e00771-17. doi: 10.1128/JVI.00771-17

Bates, J. P., Derakhshandel, R., Jones, L., and Webb, T. J. (2018). Mechanisms of immune evasion in breast cancer. *BMC Cancer* 18:556. doi: 10.1186/s12885-018-4441-3

Batram, C., Jones, N. G., Janzen, C. J., Markert, S. M., and Engstler, M. (2014). Expression site attenuation mechanistically links antigenic diversity in human papillomaviruses. *Elife* 3:e02324. doi: 10.7554/eLife.02324

Bax, L. A., Garza-Mayers, A. C., and Goldberg, M. B. (2013). Bacterial subversion of host innate immune pathways. *Science* 340, 697–701. doi: 10.1126/science.1235771

Beatty, G. L., and Gladney, W. L. (2015). Immune escape mechanisms as a guide for cancer immunotherapy. *Clin. Cancer Res.* 21, 687–692. doi: 10.1158/1078-0432.CCR-14-1860

Bets, H. J., Wolf, K., and Fields, K. A. (2009). Effector protein modulation of host cells: examples in the Chlamydia spp. *Arsenal. Curr. Opin. Microbiol.* 12, 81–87. doi: 10.1016/j.mib.2008.11.009

Bets, J. C., Lukey, P. T., Robb, L. C., McAdam, R. A., and Duncan, K. (2002). Evaluation of a nutrient starvation model of *Mycobacterium tuberculosis* persistence by gene and protein expression profiling. *Mol. Microbiol.* 43, 717–731. doi: 10.1046/j.1365-2958.2002.0779.x

Bhatia, A., and Kumar, Y. (2014). Cellular and molecular mechanisms in cancer immune escape: a comprehensive review. *Exp. Rev. Clin. Immunol.* 10, 41–62. doi: 10.1586/1744666X.2014.865519

Bi, J., and Tian, Z. (2017). NK cell exhaustion. *Front. Immunol.* 8:760. doi: 10.3389/fimmu.2017.00760

Bloom, D. C., Giordani, N. V., and Kwiatkowski, D. L. (2010). Epigenetic regulation of latent HSV-1 gene expression. *Biochim. Biophys. Acta* 1799, 246–256. doi: 10.1016/j.bbagen.2009.12.001

Bohn-Wippert, K., Tevonian, E. N., Megaridis, M. R., and Dar, R. D. (2017). Similarity in viral and host promoters couples viral reactivation with host cell migration. *Nat. Commun.* 8:15006. doi: 10.1038/ncomms15006

Brand, A., Singer, K., Kowih, G. E., Kolitzus, M., Schoenhammer, G., Thiel, A., et al. (2016). LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK Cells. *Cell Metab.* 24, 657–671. doi: 10.1016/j.cmet.2016.08.011

Cairns, R. A., Harris, I. S., and Mak, T. W. (2011). Regulation of cancer cell metabolism. *Nat. Rev. Cancer* 11, 85–95. doi: 10.1038/nrc2981

Calcinotto, A., Filipazzi, P., Grioni, M., Iero, M., De Milito, A., Ricupito, A., et al. (2016). MDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK Cells. *Cell Metab.* 24, 657–671. doi: 10.1016/j.cmet.2016.08.011

Cambier, C. J., Fallow, S., and Ramakrishnan, L. (2014). Host evasion and exploitation schemes of *Mycobacterium tuberculosis*. *Cell* 159, 1497–1509. doi: 10.1016/j.cell.2014.11.024

Cascone, T., McKenzie, J. A., Mbofung, R. M., Punt, S., Wang, Z., Xu, C., et al. (2018). Increased tumor glycolysis characterizes immune resistance to adoptive T cell therapy. *Cell Metab.* 27:e974. doi: 10.1016/j.cmet.2018.02.024

Chan, Y. K., and Gack, M. U. (2016). Viral evasion of intracellular DNA and RNA sensing. *Nat. Rev. Microbiol.* 14, 360–373. doi: 10.1038/nrmicro.2016.45

Chang, C. H., Curtis, J. D., Maggi, L. B., Faubert, B., Villarino, A. V., O’Sullivan, D., et al. (2013). Posttranscriptional control of T cell effector function by aerobic glycolysis. *Cell* 153, 1239–1251. doi: 10.1016/j.cell.2013.05.016

Chaplin, D. D. (2010). Overview of the immune response. *J. Allergy Clin. Immunol.* 125(Suppl. 2), S3–23. doi: 10.1634/jaci.2009.12.980

Chen, W., Liang, X., Peterson, A. J., Munn, D. H., and Blazar, B. R. (2008). The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. *J. Immunol.* 181, 5396–5404. doi: 10.4049/jimmunol.181.8.5396
Martelli, F., and Giannecchini, S. (2017). Polyomavirus microRNAs circulating in biological fluids during viral persistence. *Rev. Med. Virol.* 27:e1927. doi: 10.1002/rmv.1927

Martinez-López, M., Soto, M., Iborra, S., and Sancho, D. (2018). Hijacks myeloid cells for immune escape. *Front. Microbiol.* 9:893. doi: 10.3389/fmicb.2018.00893

Massoudi, W., Rottenberg, M. M. E., and Kristensen, K. (2007). Migration of African trypanosomes across the blood-brain barrier. *Physiol. Behav.* 92, 110–114. doi: 10.1016/j.physbeh.2007.05.045

Masson, J. J., Billings, H. W., and Palmer, C. S. (2017). Metabolic reprogramming during hepatitis B disease progression offers novel diagnostic and therapeutic opportunities. *Antivir. Chem. Chemother.* 25, 53–57. doi: 10.1177/2040206617701337

Maurin, M., Benoliel, A. M., Bongrand, P., and Raoult, D. (1992). Phagolysosomes of *Coxiella burnetii*-infected cells maintain an acidic pH during persistent infection. * Infect. Immun.* 60, 503–506.

McLean, K. J., and Jacobs-Lorena, M. (2017). Confers survival upon amino acid starvation. *MBio* 8:e02317–16. doi: 10.1128/mbio.02317-16

Mohme, N., Riethdorf, S., and Pantel, K. (2017). Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape. *Nat. Rev. Clin. Oncol.* 14, 155–167. doi: 10.1038/nrclonc.2016.144

Moon, Y. W., Hajjar, J., Hwu, P., and Naing, A. (2015). Targeting the structural characteristics of the binding peptides from the sporozoite antigen of *Plasmodium falciparum* to stimulate T-cell responses. *PLoS Negl. Trop. Dis.* 9:e1235106. doi: 10.1371/journal.pntd.0001235

Munn, D. H., and Bronte, V. (2016). IDO in the tumor microenvironment: immunosuppressive mechanisms and therapeutic opportunities. *J. Immunother.* 39, 1–6. doi: 10.1007/s10539-015-0109-8

Munn, D. H., and Mellor, A. L. (2016).IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance. *Trends Immunol.* 37, 193–207. doi: 10.1016/j.it.2016.01.002

Nabavi, N., Ettinger, S. L., Crea, F., Wang, Y., and Collins, C. C. (2017). “Biological and Clinical Evidence for Metabolic Dormancy in Solid Tumors Post Therapy,” in *Tumor Dormancy and Recurrence,* ed G. Meng, F. Crea, M. Abdalla, and I. M. Verheijen (Chapman: Springer International Publishing), 17–29.

Nakada-Tsukui, K., and Nozaki, T. (2016). Immune response of amebiasis to *Entamoeba histolytica*. *Front. Immunol.* 7:175. doi: 10.3389/fimmu.2016.00175

Nataraj, A., and Saha, G. (2014). “The proliferating cell hypothesis: a metabolic framework for Kaposi sarcoma,” in *Kaposi Sarcoma-Associated Herpesvirus (KSHV): role of IFI16 in maintenance of KSHV latency.* J. Virol. 90, 8822–8841. doi: 10.1128/JVI.01003-16

Norte, K. E., Caamano-Gutierrez, E., Ward, S. A., and Biagini, G. A. (2014). The proliferating cell hypothesis: a metabolic framework for Kaposi sarcoma-Associated Herpesvirus (KSHV): role of IFI16 in maintenance of KSHV latency. J. Virol. 90, 8822–8841. doi: 10.1128/JVI.01003-16

Pecora, P. J., and Capozza, T. A. (2005). Helminthic infections of the liver. *Curr. Infect. Dis. Rep.* 7, 61–70. doi: 10.1007/s11908-005-0025-x

Peters, K., Fusi, A., Nonaka, D., Priest, L., Kelly, P., et al. (2014). Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer. *Clin. Cancer Res.* 20, 926–937. doi: 10.1158/1078-0432.CCR-13-2270

Pu, Y., Ke, Y., and Bai, F. (2017). Active efflux in dormant bacterial cells - New insights into antibiotic persistence. *Drug. Resist. Updat.* 30, 7–14. doi: 10.1016/j.drup.2016.11.002

Qian, S., Fan, W., Liu, T., Wu, M., Zhang, H., Cui, X., et al. (2017). Seneca valley virus suppresses host type i interferon production by targeting adaptor proteins MAVS, TRIF, and TANK for cleavage. *J. Virol.* 91:00823–17. doi: 10.1128/JVI.00823-17

Quintard, S., Dean, P., Maresca, M., and Kenny, B. (2006). The enteropathogenic *Escherichia coli* Espf effector molecule inhibits PI-3 kinase-mediated uptake independently of mitochondrial targeting. *Cell Microbiol.* 8, 972–981. doi: 10.1111/j.1462-5822.2005.00680.x

Reddick, L. E., and Alto, N. M. (2014). Bacteria fighting back: how pathogens target and subvert the host innate immune system. *Mol. Cell.* 54, 321–328. doi: 10.1016/j.molcel.2014.03.010

Rittershaus, E. S., Baek, S. H., and Sassetti, C. M. (2013). The normalcy of dormancy: common themes in microbial quiescence. *Cell Host Microbe* 13, 643–651. doi: 10.1016/j.chom.2013.05.012

Rodrigues, V., Cordeiro-da-Silva, A., Lafortune, M., Ouaissi, A., Akharid, K., Silvestre, R., et al. (2014). Impairment of T cell function in parasitic infections. *PLoS Negl. Trop. Dis.* 8:e25567. doi: 10.1371/journal.pntd.0002556

Roser, T. (2015). Understanding the mysterious M2 macrophage through activation markers and effector mechanisms. *Mol. Immunol.* 59, 70–77. doi: 10.1016/j.molimm.2015.04.002

Sanchez, E. L., and Lagunoff, M. (2015). Viral activation of cellular metabolism. *Virology* 479, 539–618. doi: 10.1016/j.virol.2015.02.038

Seidel, J. A., Otsuka, A., and Kabashima, K. (2018). Anti-PD-1 and Anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and Limitations. *Front. Oncol.* 8:368. doi: 10.3389/fonc.2018.00368

Sharpe, A. H., and Pauken, K. E. (2018). The diverse functions of the PD1 inhibitory pathway. *Nat. Rev. Immunol.* 18, 153–167. doi: 10.1038/nri.2017.108

Shime, H., Yabu, M., Akazawa, T., Kodama, K., Matsumoto, M., Seya, T., et al. (2008). Tumor-secreted lactic acid promotes IL-23/IL-17 proinflammatory pathway. *J. Immunol.* 180, 7175–7183. doi: 10.4049/jimmunol.180.11.7175

Small, P. L., Ramakrishnan, L., and Falkow, S. (1994). Remodeling schemes of intracellular pathogens. *Science* 263, 637–639. doi: 10.1126/science.2636726

Somo, A., Bloch, S., Ippolito, J. E., and Achilleu, S. (2016). Acidic extracellular pH of tumors induces octamer-binding transcription factor 4 expression in murine fibroblasts in vitro and in vivo. *Sci. Rep.* 6:27803. doi: 10.1038/srep27803

Soto, J. A., Galvez, N. M. S., Benavente, F. M., Pizarro-Ortega, M. S., Lay, M. K., Riedel, C., et al. (2018). Human metapneumovirus: mechanisms and molecular targets used by the virus to avoid the immune system. *Front. Immunol.* 9:2466. doi: 10.3389/fimmu.2018.02466
Spranger, S., and Gajewski, T. F. (2018). Impact of oncogenic pathways on evasion of antitumour immune responses. *Nat. Rev. Cancer* 18, 139–147. doi: 10.1038/nrc.2017.117

Stjilemans, B., Calgon, G., Van Den Abbeele, J., Van Ginderachter, J. A., Magez, S., and De Trez, C. (2016). Immune evasion strategies of *trypanosoma brucei* within the mammalian host: progression to pathogenicity. *Front. Immunol.* 7:233. doi: 10.3389/fimmu.2016.00233

Tan, Z., Xie, N., Banerjee, S., Cui, H., Fu, M., Thannickal, V. J., et al. (2015). The monocarboxylate transporter 4 is required for glycolytic reprogramming and inflammatory response in macrophages. *J. Biol. Chem.* 290, 46–55. doi: 10.1074/jbc.M114.603589

Tang, J., Yu, J. X., Hubbard-Lucey, V. M., Neftelinov, S. T., Hodge, J. P., and Lin, Y. (2018). Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors. *Nat. Rev. Drug. Discov.* 17, 854–855. doi: 10.1038/nrd.2018.210

Tennant, D. A., Durán, R. V., and Gottlieb, E. (2010). Targeting metabolic transformation for cancer therapy. *Nat. Rev. Cancer* 10, 267–277. doi: 10.1038/nrc2817

Thammavongsa, V., Kim, H. K., Missiakas, D., and Schneewind, O. (2015). Staphylococcal manipulation of host immune responses. *Nat. Rev. Microbiol.* 13, 529–543. doi: 10.1038/nrmicro3521

Thangaraju, M., Cresci, G. A., Liu, K., Ananth, S., Gnanaprakasm, J. P., Browning, D. D., et al. (2009). GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon. *Cancer Res.* 69, 2826–2832. doi: 10.1158/0008-5472.CAN-08-4466

Tielen, A. G. (1994). Energy generation in parasitic helminths. *Parasitol. Today* 10, 346–352. doi: 10.1016/0169-4758(94)90245-3

Ullah, M. S., Davies, A. J., Liu, K., Ananth, S., Gnanaprakasam, J. P., Browning, D. D., et al. (2009). GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon. *Cancer Res.* 69, 2826–2832. doi: 10.1158/0008-5472.CAN-08-4466

van Kessel, K. P., Bestebroer, T. J., and van Strijp, J. A. (2014). Neutrophil-mediated phagocytosis of *Staphylococcus aureus*. *Front. Immunol.* 5:467. doi: 10.3389/fimmu.2014.00467

Vaure, C., and Liu, Y. (2014). A comparative review of toll-like receptor 4 expression and functionality in different animal species. *Front. Immunol.* 5:316. doi: 10.3389/fimmu.2014.00316

Vinay, D. S., Ryan, E. P., Pawelec, G., Talib, W. H., Stagg, J., Elkord, E., et al. (2015). Immune evasion in cancer: mechanistic basis and therapeutic strategies. *Semin. Cancer Biol.* 35, S185–S198. doi: 10.1016/j.semcancer.2015.03.004

Vitko, N. P., Spahich, N. A., and Richardson, A. R. (2015). Glycolytic dependency of high-level nitric oxide resistance and virulence in *Staphylococcus aureus*. *MBio* 6:e00045–15. doi: 10.1128/mBio.00045-15

Wahlgren, M., Goel, S., and Akhouri, R. R. (2017). Variant surface antigens of *Plasmodium falciparum* and their roles in severe malaria. *Nat. Rev. Microbiol.* 15, 479–491. doi: 10.1038/nrmicro2017.47

Wang, S., Zhang, Y., Cong, W., Liu, J., Fan, H., Xu, Y., et al. (2016). Breast cancer stem-like cells can promote metastasis by activating platelets and down-regulating antitumor activity of natural killer cells. *J. Tradit. Chin. Med.* 36, 530–537. doi: 10.1016/j.sctcm.2016.03.0071

Warburg, O. (1956). On respiratory impairment in cancer cells. *Science* 124, 269–270.

Wieland, D., Hofmann, M., and Thimme, R. (2017). Overcoming CD8+ T-cell exhaustion in viral hepatitis: lessons from the mouse model and clinical perspectives. *Dig. Dis.* 35, 334–338. doi: 10.1159/000456584

Witkowski, B., Lelièvre, J., Barragán, M. J., Laurent, V., Su, X. Z., Berry, A., et al. (2010). Increased tolerance to artemisinin in *Plasmodium falciparum* is mediated by a quiescence mechanism. *Antimicrob. Agents Chemother.* 54, 1872–1877. doi: 10.1128/AAC.01636-09

Wong, N., Ojo, D., Yan, J., and Tang, D. (2015). PKM2 contributes to cancer metabolism. *Cancer Lett.* 356(2 Pt A), 184–191. doi: 10.1016/j.canlet.2014.01.031

Wood, T. K., Knabel, S. J., and Kwan, B. W. (2013). Bacterial persister cell formation and dormancy. *Appl. Environ. Microbiol.* 79, 7116–7121. doi: 10.1128/AEM.02636-13

Wu, N. C., and Wilson, I. A. (2017). A perspective on the structural and functional constraints for immune evasion: insights from influenza virus. *J. Mol. Biol.* 429, 2694–2709. doi: 10.1016/j.jmb.2017.06.015

Zambrano-Villa, S., Rosales-Borjas, D., Carrero, J. C., and Ortiz-Ortiz, L. (2002). How protozoan parasites evade the immune response. *Trends Parasitol.* 18, 272–278. doi: 10.1016/S1471-4922(02)02289-4

Zhao, Y., Butler, E. B., and Tan, M. (2013). Targeting cellular metabolism to improve cancer therapeutics. *Cell Death Dis.* 4:e332. doi: 10.1038/cddis.2013.60

Zou, Z. Q., Wang, L., Wang, K., and Yu, J. G. (2016). Innate immune targets of hepatitis B virus infection. *World J. Hepatol.* 8, 716–725. doi: 10.4254/wjh.v8.i17.716

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Wong, Choi, Liu, Xu, Killam, Gout and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.